drugset / Trial / NCT06537505

A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

NCT06537505

Phase 2 Not yet recruiting 60 enrolled Beidahuang Industry Group General Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, phase Il trial to evaluate the efficacy and safety of microwave ablation combined with immunotherapy ± anti-angiogenic drugs in the treatment of advanced second-line and above solid tumors.

Timeline

Start
2024-08-05
Primary completion
2027-04-01
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule
Background Adebrelimab Monoclonal antibody Intravenous

Indications